Key Takeaways:
- Erasca priced 31.4M shares at $17.50 each for ~$550M in gross proceeds
- The upsized offering will dilute existing shareholders by roughly 17%
- Underwriters have a 30-day option to buy an additional 4.7M shares
Back
Erasca raises $550M in upsized stock offering, diluting existing holders
Erasca Inc. priced an upsized public offering of 31,428,572 shares at $17.50 apiece, expected to generate about $550 million in gross proceeds for the clinical-stage oncology company.
The company did not provide a statement from management regarding the offering. Erasca, which focuses on therapies for RAS/MAPK pathway-driven cancers, said the shares are being sold by the company itself, with no selling shareholders involved.
The offering represents roughly 17% dilution based on the company's previously outstanding share count. Erasca has granted underwriters a 30-day option to purchase up to an additional 4,714,285 shares at the same price, which could bring total proceeds to about $632.5 million if fully exercised. The transaction is expected to close July 15, subject to customary closing conditions.
The capital raise provides Erasca with substantial runway to advance its clinical pipeline, though the dilution overhang typically pressures stock prices in the near term. The company's next catalyst will be clinical data readouts from its RAS/MAPK program, which investors will evaluate against the backdrop of the newly raised capital.
This article is for informational purposes only and does not constitute investment advice.
